Loading organizations...
§ Private Profile · Medford, MA, USA
Develops a non-invasive diagnostic platform for bladder cancer detection using atomic force microscopy and machine learning.
Based in Massachusetts, Cellens develops a non-invasive diagnostic platform that utilizes atomic force microscopy and machine learning technology for early bladder cancer detection. The company combines computational artificial intelligence with mechanobiology to analyze cell surface properties at high resolution, creating a clinical screening tool for the broader healthcare and medical device sectors. Backed by early venture capital, the enterprise secured initial seed funding from lead investor SOSV in January 2022 and subsequently initiated an additional financing round in early 2026 to support ongoing development. The core technology originated from research conducted at Tufts University in collaboration with Professor Dr. Igor Sokolov, leading the startup to win two distinct tracks and the Ricci Interdisciplinary Prize at a university venture competition. Cellens was officially founded in 2020 by co-founders Jean Phuong Pham, Jonas Pirkl, and XueYing Wang.
Cellens has raised $6.5M across 1 funding round.
Cellens has raised $6.5M in total across 1 funding round.
Cellens has raised $6.5M across 1 funding round. Most recently, it raised $6.5M Seed in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 23, 2025 | $6.5M Seed | SOSV | American Cancer Society, Blackwood, Cancer Fund, Kolon Investment, Labcorp, TIE Angels Boston, Tufts University | Announced |
Cellens has raised $6.5M in total across 1 funding round.
Cellens's investors include SOSV, American Cancer Society, Blackwood, Cancer Fund, Kolon Investment, Labcorp, TiE Angels Boston, Tufts University.